CELLTRION WILL SUPPLY ITS COVID-19 TREATMENT WITHOUT PROFIT MARGIN IN S. KOREA

Highlights –

• Celltrion will supply its COVID-19 treatment without profit margin in S. Korea.
• Celltrion’s CT-P59 began to be supplied to local medical institutions on Wednesday.
• The company has also planned to supply the treatment globally after keeping enough for all Koreans.
• Celltrion is said to be in talks with the U.S Food and Drug Administration.